Scancell (LON:SCLP) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

Key Points

• Technical sell signal: Scancell shares fell below their 50‑day moving average of GBX 12.49, trading as low as GBX 12 and last at GBX 12.25 on heavy volume (~984,263 shares).
• Weak recent financials: The company has a market cap of £124.64M, a negative P/E of -21.84, reported GBX (0.55) EPS last quarter and analysts forecast about -2.536 EPS for the current fiscal year.
• Clinical-stage biotech: Scancell develops immunotherapies (Immunobody® and Moditope®); lead candidate iSCIB1+ has shown monotherapy activity and added benefit with checkpoint inhibitors in the ongoing Phase 2 SCOPE trial for advanced melanoma.

Shares of Scancell Holdings plc (LON:SCLP - Get Free Report) crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 12.49 and traded as low as GBX 12. Scancell shares last traded at GBX 12.25, with a volume of 984,263 shares traded.

Scancell Price Performance

The company has a market cap of £124.64 million, a price-to-earnings ratio of -21.84 and a beta of 0.35. The company has a current ratio of 0.56, a quick ratio of 13.01 and a debt-to-equity ratio of -193.29. The company has a fifty day moving average price of GBX 12.49 and a two-hundred day moving average price of GBX 10.73.

Scancell (LON:SCLP - Get Free Report) last issued its earnings results on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%. As a group, equities research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.